Zobrazeno 1 - 10
of 50
pro vyhledávání: '"Albert Isidro-Llobet"'
Characterisation of IL-23 receptor antagonists and disease relevant mutants using fluorescent probes
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-11 (2023)
Abstract Association of single nucleotide polymorphisms in the IL-23 receptor with several auto-inflammatory diseases, led to the heterodimeric receptor and its cytokine-ligand IL-23, becoming important drug targets. Successful antibody-based therapi
Externí odkaz:
https://doaj.org/article/86032f589b894097a542dab777945e85
Autor:
Jak Grimes, Sapna Desai, Neil W. Charter, James Lodge, Rita Moita Santos, Albert Isidro‐Llobet, Andrew M. Mason, Zining Wu, Lawrence A. Wolfe III, Lakshmi Anantharaman, Andrew Green, Angela M. Bridges, Deidre A. Dalmas Wilk, Andrew J. Brown
Publikováno v:
Pharmacology Research & Perspectives, Vol 7, Iss 6, Pp n/a-n/a (2019)
Abstract Activation of MrgX2, an orphan G protein‐coupled receptor expressed on mast cells, leads to degranulation and histamine release. Human MrgX2 binds promiscuously to structurally diverse peptides and small molecules that tend to have basic p
Externí odkaz:
https://doaj.org/article/d52477c4710a45b380964101c0429cd7
Autor:
Naresh M. Venneti, Ganesh Samala, Rana M. I. Morsy, Lawrence G. Mendoza, Albert Isidro-Llobet, Janine K. Tom, Subha Mukherjee, Michael E. Kopach, Jennifer L. Stockdill
Publikováno v:
Journal of the American Chemical Society. 145:1053-1061
Peptides are steadily gaining importance as pharmaceutical targets, and efficient, green methods for their preparation are critically needed. A key deficiency in the synthetic toolbox is the lack of an industrially viable peptide desulfurization meth
Characterisation of IL-23 receptor antagonists and disease relevant mutants using fluorescent probes
Association of single nucleotide polymorphisms in the IL-23 receptor with the several auto-inflammatory diseases, led to the heterodimeric receptor and its cytokine-ligand IL-23, becoming important drug targets. Successful antibody-based therapies di
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::14c8cad214b114871293bf05d19111b7
https://doi.org/10.21203/rs.3.rs-2118755/v1
https://doi.org/10.21203/rs.3.rs-2118755/v1
Autor:
Mark R. Harpel, Ghotas Evindar, Shenaz Bunally, David G. Washburn, Steve Wilson, Joanne Prendergast, Scott G. Summerfield, Katrina Rivera, Chun-wa Chung, Julien C. Vantourout, Steven R. Skinner, Neil Young, Xiaopeng Bai, Christopher C. Arico-Muendel, Albert Isidro-Llobet, Rakesh Lad, William Traylen, Graham L. Simpson, Josephine Yuen, Letian Kuai, Paul Scott-Stevens, Kim Lambert, Sandeep Pal, Saul Needle, Andrew M. Mason, Michael J Hobbs, Emma V. Edgar, Richard Snell, Lara S. Kallander, Eric X Shi, Lisa M. Shewchuk, Dennis A. Holt, Allan J. B. Watson
Publikováno v:
Bioconjugate Chemistry. 32:279-289
Reducing the required frequence of drug dosing can improve the adherence of patients to chronic treatments. Hence, drugs with longer in vivo half-lives are highly desirable. One of the most promising approaches to extend the in vivo half-life of drug
Autor:
Friederike M. Dannheim, Nicola Ashman, Hikaru Seki, David R. Spring, Jason S. Carroll, Xiaoxu Ou, Jonathan D Bargh, Andrew J. Counsell, Stephen J. Walsh, Jeremy S. Parker, Albert Isidro-Llobet, Abigail R. Hanby, Yuri Takada, Elaine Fowler
Publikováno v:
Chemical Society Reviews. 50:1305-1353
Antibody-drug conjugates (ADCs) harness the highly specific targeting capabilities of an antibody to deliver a cytotoxic payload to specific cell types. They have garnered widespread interest in drug discovery, particularly in oncology, as discrimina
Autor:
Sascha Röth, Bill Carton, Preethi S. Sathyamurthi, Matthew Watt, Thomas J. Macartney, Kwok-Ho Chan, Albert Isidro-Llobet, Agnieszka Konopacka, Markus A. Queisser, Gopal Sapkota
Publikováno v:
SSRN Electronic Journal.
Autor:
Nicola Ashman, Jonathan D Bargh, Albert Isidro-Llobet, Stephen J. Walsh, David R. Spring, Jason S. Carroll
Publikováno v:
Chemical communications (Cambridge, England). 57(28)
A novel enzyme cleavable linker for antibody-drug conjugates is reported. The 3-O-sulfo-β-galactose linker is cleaved sequentially by two lysosomal enzymes - arylsulfatase A and β-galactosidase - to release the payload in targeted cells. An α-HER2
Antibody–Drug Conjugates (ADCs) are now established as a major class of therapeutics for the clinical treatment of cancer. The properties of the linker between the antibody and the payload are proven to be critical to the success of an ADC. Althoug
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eb501c7603723d1406a954cf52c184e8
https://www.repository.cam.ac.uk/handle/1810/294617
https://www.repository.cam.ac.uk/handle/1810/294617
Autor:
Subha Mukherjee, Christine A. Arbour, Michael E. Kopach, Jennifer L. Stockdill, Albert Isidro-Llobet, Kayla J Belavek, Janine K. Tom, Rooha Tariq
Publikováno v:
The Journal of organic chemistry. 84(2)
We establish herein conditions for the cyclization of unprotected N-acyl urea-linked peptides to form macrocyclic peptides mediated by N-terminal cysteine. We report a detailed investigation of the parameters of the reaction, including variation of t